Efficacy and safety of Camrelizumab and AVD in the first-line treatment of classic Hodgkin's lymphoma.
- Author:
Ke ZHAO
1
;
Hua Qing WANG
1
;
Lin LI
1
;
Teng SONG
1
;
Shu Ping LI
1
;
Ming Han QIU
1
Author Information
- Publication Type:Journal Article
- MeSH: Antibodies, Monoclonal, Humanized/adverse effects*; Hodgkin Disease/drug therapy*; Humans; Vinblastine
- From: Chinese Journal of Hematology 2022;43(5):431-434
- CountryChina
- Language:Chinese
